IMV Inc. (IMV)
| Market Cap | 181.01M |
| Revenue (ttm) | 236,078 |
| Net Income (ttm) | -27.34M |
| Shares Out | 67.71M |
| EPS (ttm) | -0.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $2.66 |
| Previous Close | $2.61 |
| Change ($) | 0.05 |
| Change (%) | 1.92% |
| Day's Open | 2.61 |
| Day's Range | 2.55 - 2.68 |
| Day's Volume | 143,228 |
| 52-Week Range | 2.18 - 6.82 |
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to announce First Quarter 2021 Results and host conference call and Webcast on May 12, 2021
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference
Investors need to pay close attention to IMV stock based on the movements in the options market lately.
Following feedback from the FDA, IMV Inc (NASDAQ: IMV) has inked an agreement with Merck & Co (NYSE: MRK) to initiate a Phase 2B trial evaluating IMV's lead compound, maveropepimut-S (DPX-Survivac), in ...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)-- #DLBCL--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the "Company" or "IMV") (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)---- $IMV--IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today...
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines agai...
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - On national TV Sat. Dec 12 & Sun. Dec 13, 2020 - BTV-Business Television spotlights the newest mining, cannabis, tech and pharmaceutic...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccin...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against inf...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
IMV Inc. (IMV) CEO Frederic Ors on Q3 2020 Results - Earnings Call Transcript
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Third Quarter 2020 Financial Results and Provides Clinical Update
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the Company's T ce...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Report Third Quarter 2020 Results and Present Biomarkers
HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Appili Announces Additional $6.3MM US Funding for its ATI-1701 Biodefense Program, working with Ology Bio on a vaccine candidate agai...
HALIFAX, Nova Scotia--(BUSINESS WIRE)---- $IMV #AntibioticDeveloper--Investigators enrolled and dosed the first cluster of participants in Appili's Phase 2 CONTROL clinical trial evaluating favipiravir ...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Re-establishes At-the-Market Facility
IMV has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
Canada's IMV is a small but high-profile biotechnology company engaged in the development of a COVID-19 vaccine.
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious di...
IMV Inc. (IMV) CEO Frederic Ors on Q2 2020 Results - Earnings Call Transcript
IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. Announces Second Quarter 2020 Financial Results
IMV is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV (NASDAQ: IMV) shares are trading higher on Wednesday after the company announced it has received CA$4.75 million ($3.59 million) in funding from the Canadian government agencies for a COVID-19 vacci...
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious d...
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. to Announce Second Quarter 2020 Results and Host a Conference Call and Webcast on August 12, 2020
As of late, it has definitely been a great time to be an investor in IMV Inc. (IMV).
IMV saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Good news for Moderna was bad news for several of its rivals.
IMV Inc. (NASDAQ: IMV) shares surged on Tuesday after the company provided an update on its vaccine candidate for COVID-19.
Imv Inc (NASDAQ: IMV) share are ripping higher on above-average volume following an update by the company on its coronavirus vaccine program.
IMV Inc. (IMV) CEO Frederic Ors on Q1 2020 Results - Earnings Call Transcript
IMV INC (IMV) delivered earnings and revenue surprises of -27.27% and 27.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMV, Inc. (IMV) CEO Frederic Ors on Q4 2019 Results - Earnings Call Transcript
Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.
IMV plans to develop a vaccine candidate using its lipid-based delivery platform, DPX technology, for the treatment of coronavirus disease. Stock rises.
Micro-cap Canadian biopharma Imv Inc (NASDAQ: IMV) said Wednesday that it is advancing the clinical development of a DPX-based vaccine candidate for the coronavirus, joining a number of biotechs working...
IMV INC (IMV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About IMV
IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a ... [Read more...]
| Industry Biotechnology | Founded 2000 |
| Stock Exchange NASDAQ | Ticker Symbol IMV |
Financial Performance
In 2020, IMV Inc.'s revenue was 301,000, a decrease of -47.01% compared to the previous year's 568,000. Losses were -34.86 million, 27.4% more than in 2019.